PhaseBio Pharmaceuticals Net Cash/Marketcap

Net Cash/Marketcap of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Cash/Marketcap growth rates and interactive chart.


Highlights and Quick Summary

Current Net Cash/Marketcap of PhaseBio Pharmaceuticals is $-0.142 (as of December 30, 2020)
  • Net Cash/Marketcap for the quarter ending September 29, 2021 was $-0.312 (a 4.56% increase compared to previous quarter)
  • Year-over-year quarterly Net Cash/Marketcap decreased by -11.72%
  • Annual Net Cash/Marketcap for 2020 was $-0.142 (a -59.9% decrease from previous year)
  • Annual Net Cash/Marketcap for 2019 was $-0.353 (a -88.52% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Cash/Marketcap of PhaseBio Pharmaceuticals

Most recent Net Cash/Marketcapof PHAS including historical data for past 10 years.

Interactive Chart of Net Cash/Marketcap of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Net Cash/Marketcap for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.0 $0.0
2020 $0.0 $0.0
2019 $0.0 $0.0 $0.0 $0.0 $0.0
2018 $0.0 $0.0 $0.0

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.